Article and Video CATEGORIES

Cancer Journey

Search By

Promising Early Results with Immunotherapy for Mesothelioma
Author
GRACE Videos and Articles

WCLC_2015_03_Mesothelioma_Immunotherapy_Promising_Early_Results

 

Drs. Leora Horn, Ben Solomon, & Jack West review early promising data on the potential activity of immune checkpoint inhibitors in the treatment of malignant pleural mesothelioma.

[powerpress]

Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

Dr. West:  Turning to the issues of what’s emerging in mesothelioma, it seems that there’s a lot of interest in immunotherapies in this setting. Any sense of early data in that, how hopeful you are?

Dr. Solomon:  So, it was with pembrolizumab, and again, a small study, and a response rate of about 29%, and I think that’s encouraging, and I think this is in patients who had prior platinum pemetrexed, and this is a setting where there isn’t a standard second-line treatment, so I think that sort of response rate, again, is a meaningful response rate, and there are a number of other studies that are going with the other different PD-1 or PD-L1 inhibitors, alone or in combination with CTLA-4 inhibitors.

Dr. Horn:  The pembrolizumab study, from what I remember, was only in PD-L1-positive patients.

Dr. Solomon:  I think that’s right, and we may talk about PD-L1 as a biomarker later, but I think an interesting observation was that the didn’t find that the degree of PD-L1 scoring correlated with the likelihood of response, in mesothelioma.

Next Previous link

Previous PostNext Post

Related Content

Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora
Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated.